This innovative machine rolls on. Biotech giant Vertex Pharmaceuticals (VRTX -0.82%) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive phase 3 results for exciting candidates. The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal somewhere down the road. Let's find out what it is and what it could mean for investors. Straight out of the playbook Firs ...